CASE REPORT
A 56-year-old patient with pigeon breeder’s lung, with fibrosis and sepsis-related cardiogenic shock in the course of fungal-bacterial infection – case report
1
Department of Internal Medicine, Pneumonology, Allergology and Clinical Immunology, Military Institute of Medicine – National Research Institute, Warsaw, Poland
Corresponding author
Michał Rząd
Department of Internal Medicine, Pneumonology, Allergology and Clinical Immunology, Military Institute of Medicine – National Research Institute, Szaserów 128, 04-141, Warsaw, Poland
Department of Internal Medicine, Pneumonology, Allergology and Clinical Immunology, Military Institute of Medicine – National Research Institute, Szaserów 128, 04-141, Warsaw, Poland
KEYWORDS
TOPICS
Biological agents posing occupational risk in agriculture, forestry, food industry and wood industry and diseases caused by these agents (zoonoses, allergic and immunotoxic diseases)Prevention of occupational diseases in agriculture, forestry, food industry and wood industry
ABSTRACT
Hypersensitivity pneumonitis (HP) is a granulomatous interstitial disease that develops in genetically predisposed individuals as a result of an immune response to inhaled antigens. The case is presented of a 56-year-old male with HP with fibrosis, accompanied by severe respiratory failure (requiring HFNOT), significant oedema of the lower extremities, and a large amount of fluid in the right pleural cavity. The patient was initially in circulatory and respiratory failure, requiring infusion of catecholamines. During hospitalization thoracocentesis was performed, complicated by pneumothorax/lung expansion failure. Angio-CT revealed a pulmonary embolism. Targeted antibiotic therapy with voriconazole, meropenem and colistin, as well as bedside rehabilitation, resulted in the stabilization of the patient and improvement of his general condition. The patient was discharged home in a stable condition with the recommendation of home oxygen therapy.
REFERENCES (19)
1.
Sahin H, Kaproth-Joslin K, Hobbs SK. Hypersensitivity Pneumonitis. Semin Roentgenol. 2019;54(1):37–43. doi:10.1053/j.ro.2018.12.004.
2.
Rea G, Bocchino M, Lieto R, et al. The Unveiled Triad: Clinical, Radiological and Pathological Insights into Hypersensitivity Pneumonitis. J Clin Med. 2024;13(3):797. doi:10.3390/jcm13030797.
3.
Szafrański W. Analiza Grupy Chorych na śródmiąższowe Choroby płuc Hospitalizowanych w Latach 2000–2009 na Oddziale Płucnym Wojewódzkiego Szpitala w Radomiu. Adv Respir Med. 2012;80(6):523–532. doi:10.5603/ARM.27546.
4.
Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(3):e36-e69. doi:10.1164/rccm.202005-2032ST.
5.
Hamblin M, Prosch H, Vašáková M. Diagnosis, course and management of hypersensitivity pneumonitis. Eur Respir Rev Off J Eur Respir Soc. 2022;31(163):210169. doi:10.1183/16000617.0169-2021.
6.
Szturmowicz M, Garczewska B, Jędrych ME, et al. The value of serum precipitins against specific antigens in patients diagnosed with hypersensitivity pneumonitis – retrospective study. Cent-Eur J Immunol. 2019;44(4):390–394. doi:10.5114/ceji.2019.92791.
7.
Blanchet MR, Israël-Assayag E, Cormier Y. Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and in vitro. Am J Respir Crit Care Med. 2004;169(8):903–909. doi:10.1164/rccm.200210-1154OC.
8.
Fernández Pérez ER, Sprunger DB, Ratanawatkul P, et al. Increasing Hypersensitivity Pneumonitis-related Mortality in the United States from 1988 to 2016. Am J Respir Crit Care Med. 2019;199(10):1284–1287. doi:10.1164/rccm.201807-1258LE.
9.
Barnes H, Troy L, Lee CT, Sperling A, Strek M, Glaspole I. Hypersensitivity pneumonitis: Current concepts in pathogenesis, diagnosis, and treatment. Allergy. 2022;77(2):442–453. doi:10.1111/all.15017.
10.
De Sadeleer LJ, Hermans F, De Dycker E, et al. Effects of Corticosteroid Treatment and Antigen Avoidance in a Large Hypersensitivity Pneumonitis Cohort: A Single-Centre Cohort Study. J Clin Med. 2018;8(1):14. doi:10.3390/jcm8010014.
11.
Morisset J, Johannson KA, Vittinghoff E, et al. Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hyper-sensitivity Pneumonitis. Chest. 2017;151(3):619–625. doi:10.1016/j.chest.2016.10.029.
12.
Fiddler CA, Simler N, Thillai M, Parfrey H. Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis-A single-centre experience. Clin Respir J. 2019;13(12):791–794. doi:10.1111/crj.13086.
13.
Ferreira M, Borie R, Crestani B, et al. Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): A retrospective, multicentric, observational study. Respir Med. 2020;172:106146. doi:10.1016/j.rmed.2020.106146.
14.
Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718–1727. doi:10.1056/NEJMoa1908681.
15.
Sobiecka M, Szturmowicz M, Lewandowska K, et al. Chronic hypersensitivity pneumonitis is associated with an increased risk of venous thromboembolism: a retrospective cohort study. BMC Pulm Med. 2021;21(1):416. doi:10.1186/s12890-021-01794-y.
16.
Brims FJH, Maskell NA. Ambulatory treatment in the management of pneumothorax: a systematic review of the literature. Thorax. 2013;68(7):664–669. doi:10.1136/thoraxjnl-2012-202875.
17.
Nosotti M, Leiva-Juarez M, D’Ovidio F, et al. Survival After Lung Transplantation for Chronic Hypersensitivity Pneumonitis: Results From a Large International Cohort Study. Transpl Int Off J Eur Soc Organ Transplant. 2022;35:10450. doi:10.3389/ti.2022.10450.
18.
Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2021;40(11):1349–1379. doi:10.1016/j.healun.2021.07.005.
19.
Jacobs SS, Krishnan JA, Lederer DJ, et al. Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(10):e121-e141. doi:10.1164/rccm.202009–3608ST.
Share
RELATED ARTICLE
| eISSN: | 1898-2263 |
| ISSN: | 1232-1966 |
Improvement of visual identification of the journal - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher Education allocated to the activities of disseminating science.
Generation of the DOI (Digital Object Identifier) - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher
© 2006-2024 Journal hosting platform by Bentus
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
